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ÌN THE UNITED STATES DISTRICT COURT
FOR TIIE DISTRICT OF COLUMBIA

STATE ÒF MARYLAND, et al.
by Attorney General I. Joseph Curran, Jr.
200 S t Paul Place
Baltimore, Maryland 21202.
Civ No. 1:04CV01398 (RMC)
Plaintiffs,
v.
PËRRIGO COMPANY, étal.
515 Eastern Avenue .
Allêgaù, MI 49010
Defendants.

FINÂL ORDER AND STIPULATED PERM ANENT INJUNCTION
; :

W HEREAS Plaintiffs, the States and Commonwealths o f Maryland, Colorado, Ohio,

Florida, Michigan, Alabama, Alaska, Arizona, Arkansas, California, Connecticut, Delaware,
D istrict o f Columbia, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana,
M aine, Massachusetts, M ississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey,
'N ëw Mexico, New York, North Dakota, Northern M ariana Islands, Oklahoma, Oregon,
Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas,
Utah, Vermont, Virgin Islands, Virginia, Washington, W est Virginia, Wisconsin and Wyoming
(“Plaintiff States” or “States”), filed their Complaint on August 17,2004 pursuant tó Section 1 o f
:,
’
.
'
!.
The Shermain Act, 15 U .S.d. § 1 and Section 16 o f the Clayton Act, 15 U.S.C. § 26, and 28
Ü.S.G. §§ 1331, 1337, and seeking civil penalties, injunctive and other equitable relief for

violations of state antitrust, consumer protection and/or unfair competition statutes and related
. state laws;
AND WHEREAS, in conjunction with the filing o f this Einal Order and Stipulated
Permanent Injunction. (‘‘Èinai Order”), Plaintiff States and Defendant Alpharma, Me., by their
respective attorneys, have stipulated and agreed to entry by the Court o f this Final Order w ithout,
trial or adjudication. 6 f any issue o f fact or law;
AND W HEREAS, this Final Ôrder is entered for settlement purposes only and does not
constitute any evidence ¿gainst, Or. an admission o f liability or any issue of fact or law, other than
jurisdictional, by Defendant Alpharma, Inc.;
AND WHEREAS, Défendant Alpharma, Inc. agrees to be bound by the provisions o f this
Final Order pending its approval by the Court;
AND WHEREAS, Defendant Alpharma, Inc. has rescinded the agreement challenged in
the Complaint and this Final Order requires Defendant Alpharma, Inc. to refrain from entering
into similar agreements in the future to remedy the competition lost as alleged in the Complaint;
AND W HEREAS, another aspect o f this Final Order is the payment by Defendant
Alpharma, Inc. ôf 1) $166,566.50 to the Plaintiff States and o f 2) $333,333.50 to the National
Association 6 f Attorneys General Antitrust Enforcement Training and Education Fund Account,
representing equitable relief and/or settlement payments in lieu o f civil penalties;
AND W HEREAS, Défendant Alpharma, Inc. will pay $248,863.25 to Liaison Cohrisel for
the Plaintiff States in attorneys' fees and costs of investigation;
■■
.
i.
AND WHEREAS, Defendant Alpharma, Inc. has represented to the Plaintiff States that the
'
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-

relief required below can and will be made and that Defendant Alpharma, Inc. will later raise nd
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claim of hardship or difficulty as grounds for asking the Court to modify any o f the terms of the
relief contained below;
AND WHEREAS, Defendant Alpharma, Inc., without admitting that it has violated any
provision o f federal or state law, agrees to the entry o f this Final Order;
NOW THEREFORE, before any testimony is taken, without trial or adjudication o f any
issue o f feet or law, and upon consent of the parties, it is

ORDERED, ADJUDGED AND DECREED THAT:

L Jurisdiction and Venue
A. This Court has jurisdiction over Defendant Alpharma, Inc. (“Alpharma”) and thé subject
matter o f this action. Alpharma’s activities, including the acts and practices alleged in
Plaintiff States’ Complaint, are in or affecting commerce, as “commerce” is defined in 15
U.S.C. § 44.
B. Venue is prôper in this Court under Section 12 o f the Clayton Act, 15 U.S.C. § 22 and 28
U .S.C §§ 1391(b) and (c).
C. The Complaint states à claim upon which relief may be granted against Alpharma pursuant
to the statutes cited therein.
D. This case is a proper base for the issuance o f a permanent injunction. The Plaintiff States
haVe authority pursuant to Section 16 o f the Clayton Act, 15 U.S.C. § 26 and pursuant to
state statutes cited in the Complaint to seek the relief requested.
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È. Alpharma waives all rights tò appeal dr otherwise challenge or contest the validity o f this
Final Order:
II. Definitions
IT IS FURTHER ORDERED, ADJUDGED AND DECREED THAT, as used in this
Final Order:
A.

“Alpharma” means Alpharma, Inc. and its officers, directors, employees, agents and
representatives, successors and assigns; subsidiaries, divisions, groups and affiliates
controlled by Àlpharmà, Inc.; and the officers, directors, employees, agents and
representatives, successors and assigns o f each.

B.

“ Ì 80-day Exclusivity Period” means the six month market exclusivity period provided to
the First Filer of àn ÀNDA Under 21 U.S.C. § 355(j), ef seq.

C.

“Agreement” means anything that would constitute a contract, combination, or conspiracy
within the meaning o f Section 1 o f the Sherman Act, 15 U.S.C. § 1, regardless Ofwhether
such contract, combination, or conspiracy is in restraint o f trade.

D;

“Agreement Subject to Notification” means an Agreement in or affecting Coitiinerce in
which a pârty to the Agreement agrees to refrain from, or to limit for any period o f time,
thè research, development, manufacture, marketing, distribution of sale o f an ANDA Drug
Product that it Controls and that is O f The Same Kind as another ÀNDÀ DrugProduct
Controlled by another party to the Agreement

E.

“ANDA” means an Abbreviated New Drug Application, as defined under
21U.S.C.§ 355(j),

seq.

.

4.
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F.

“ANDA Drug Product” means à finished Dosage Form that (1) contains a drug substance
generally, but not necessarily in association with one or more other ingredients as defined in
21 C.F.R. § 314.3(b), and (2) is the subject o f an ANDA filed with or approved by ihe
FDA.

G.

“Commerce” bas the same definition as it has in 15 U.S.C. § 44.

H.

“Commission” means the Federal Trade Commission.

I.

“Controi”hleahS, in connection with an ANDA Drug Product, to (1) exclusively distribute an
AND A Drug Product, (2) have the rights to an ANDA Drug Product accruing from the
FDA’s approval o f an ANDA, or (3) be in a position to obtain such rights if die FDA were
to approve an ANDA that has been filed with the FDA.

J.

“Date o f the Agreement” means the date the Agreement is executed or otherwise goes into
effect

K.

‘^Dosage Form” means a category o f drug delivery, including, but not limited to, the
following categories: (a) tablets, (b) capsules, (c) liquids administered orally, (d) liquids
’ administered intravenously or subcutaneously, (e) nasal spays, (f) transdermal patches, and
’ (g) suppositories.

L.

“Enter into” means join, participate in, implement, adhere to, maintain, organize, enforce, or
facilitate.

hÆ.
N.

.

“First Commercial Marketing” has the same meaning it has in. 21 C.F.R. §314.107(c)(4).
“ First Filer of an ANDA” means the party whom the FDA determines is entitled to or
eligible for, under 21 U.S.C. § 355(jj, et seq., a right to a 180-day Exclusivity Period that
has not ÿet expired.

'‘0
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o.

“FDA” means the Ütiited Strifes Food arid Drug Âdmimstràtion.

P.

4‘Liaison Counsel for the Plaintiff States” means counsel for the States o f Maryland,
Colorado, Ohio, Florida and Michigan^

Q-

‘‘Marketing Type” means the following two categories: over-the-counter (“OTC”) and
prescription (“Rx”). For purposes o f this Final Order, an ANDA Drug Product is in the OTC
category if its ANDA references an NDA for an OTC drug product and is in the Rx category
if its ANDA references an NDA for an Rx drug product.

R.

“NDA” means aN ew D rug Application, as definedunder21 U.S.C. § 355(bj.

S. ■ “O f Tlie Same Kind” means to 1) have the same Dosage Form, 2) contain the same, and
only the same activé pharmaceutical ingredients), and 3) be of the same Marketing Type,
- ': t:

“Patent Infringement Claim” means any written allegation of patent infringement, whether
or riot included in a complaint filed with a court of law.

■ u.

“Person” means both trahirai persons and artificial persons, including, blit not limited to,
corpbrâtioüs, unincorporated entities, and governments.

V.

“Plaintiff States” means the States and Commonwealths o f Maryland, Colorado, Ohio,
Florida, Michigan, Alabama, Alaska, Arizona, Arkansas, California, Connecticut, Delaware,
District o f Columbia, Georgia, Hawaii, Idaho, minois, Indiana, Iowa, Kentucky; Louisiana,
Maine, Massachusetts, Mississippi, Montana, Nebraska, Nevada, New. Hampshire, New
jersey, New Mexico, New York, North Dakota, Northern Mariana Islands, Oklahoma,
Oregori, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota,
Tennessee, Texas, Utah, Vermont, Virgin Islands, Virginia, Washington, W est Virginia,
Wisconsin^ and Wyoming.
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itt* M onetary Relief
IT 1$ FURTHER O to E R E D , ADJUDGED AND DECREED THAT, not later than
three (3 j days ¡after entry o f this Final Order, Alphanna shall pay 1) the sum o f $166*666.50 to the
Pl&mtiffStates and 2)the sum o f $333,333.50 to the National Association o f Attorneys General
Antitrust Training and Bducation Fund Account (“ATE Fund Account”) under the following
terms and conditions:
A.

The payment to the Plaintiff States must be made by wire transfer, certified check or other
guaranteed funds made payable to and delivered as directed by the Plaintiff States. Alphanna
shall have or retain fto dominion, control or title to the monies transferred to or at the
direction of die Plaintiff States, and said monies shall be used at the sole discretion of
the Attorney General in each Plaintiff State and according to the terms o f this Final Order.
The Attorney General in each Plaintiff State may use these funds consistently with .
his/her state laws for ahy o f the following purposes: 1) payment o f investigative fees and
costs; 2) antitrust dr consumer protection law enforcement; 3) deposit into a state antitrust, or
. Consumer protection revolving fund; or 4) use in accordance with state law.1 All funds paid
to the Plaintiff States or to the Liaison Counsel for the Plaintiff States pursuant tb this Final
Order shall he deposited into funds administered by the Plaintiff States or their escrow agent
The payment to the ATE Fund Account must be made by wire transfer, certified'check or
other guaranteed funds made payable to the ATE Fund Account and delivered as directed by
the Plaintiff States, Upon entry o f this Order, Alpharma relinquishes all dominion, control

1With respect to the State o f Colorado, its apportionment shall be used first for
reimbursement o f Colorado^ actual costs and attorneys fees and second, to be held in trust by the
Attorney General for future consumer education, consumer fraud or antitrust enforcement efforts.
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and title'to the monies' transferred to the ATÉ Fund Account and agrees that said monies
shall constitute a contnbution to the ATE Fund Account.
C.

Alpharma shall have no right to challenge the Plaintiff States’ choice o f remedies under
Paragraph ÜÍ o f this Final Order. Alpharma shall have no right to contest the manner in
which the fluids are utilized.

D.

Àïphàiïna warranté that, as b f the date o f this Final Order, neither it nor any o f its affiliates, is
insolvent, nor will any payment to the Plaintiff States and die ATE Fund Account render it
or any o f its affiliates insolvent, within the meaning o f aiid/or for thé purposes o f the United
States Bankruptcy Code. If a casé is commenced with respect to Alpharma or ahy o f its
affiliates, under Tide 11 Ofthè Ünited States Code (Bankruptcy), or a tmstee, receiver or
conservator is appointed under any similar law, and in the event o f the entry o f á final order
o f a Court o f competent jurisdiction determinmg the payment o f the principal amount o f the
payment to the Plaintiff States or the ÁTE Fund Account, and any accrued intemst, Or any
portion thereof, by or oh behalf o f Alpharma or any affiliate o f Alpharma, to b ek preference,
voidable transfer, fraudulent transfer or similar transaction, and if pursuant to an order o f a
court o f compétent jurisdiction monies paid by Alpharma or any o f its affitiates;lo the
Plaiiitiff States Or to the ATË Fund Account pursuant to this Final Order either hot delivered
Or are returned to Alpharma or any o f its affiliates, or the trustee, receiver, or
conservator appointed by a court in any bankruptcy proceeding with respect to Alpharma or
any Of its affiliates, then this Final Order shall be subject to termination and cancellation.
. Such termination and cancellation will be the sole and exclusive remedy o f the Plaintiff
. States for breach o f this warranty.

-

s

E.

in accordance With 31 U.S.C, § '7701, Alpharma is hereby required, unless it has done so
already, to furnish to the Plaintiff States its taxpayer identification number, which shall be
used for collecting and reporting on any delinquent amount arising out o f Alpharina’s
relationship with the government

IV. Prohibited Agreements
IT IS FURTHER ORDERED, ADJUDGED AND DECREED THAT Alpharma is
enjoined from Entering into, or attempting to Enter into, directly or indirectly, or through any
:corporate or other device, any Agreement in or affecting Commerce with any other Person in
which:.
A.

a party to the Agreement agrees to refrain from, or to limit, for any period, o f time, the
research, development, manufacture, marketing, distribution or sale o f an ANDA Drug
Product that it Controls and that is O f The Same Kind as another ANDA Drag Product
Controlled by another party to the Agreement and

B.

a party to the Agreement is the First Filer o f an ANDA with respect to:
(1) any ANDA Drug Product that is the subject o f such Agreement, or
(2) any ANDA Drag Product that is O f The Same Kind as any ANDA Drug Product that is a
subject of siich Agreement.

PROVIDED, HOW EVER, THAT for purposes o f Paragraph IV only, an ANDA Drag Product
shall not include an ANDA withdrawn from the FDA more than six (6) months prior to the Date o f
. the Agreement

;

PROVIDED FURTHER THAT nothing in Paragraph IV shall prohibit the First Filer o f an
ANDA from agreeing to refrain from marketing, distributing, or selling the ANDA Drug Product
referenced by such ANE)A (“the First Filer’s ANDA Drug Product”) for a period o f time lasting no
more than 180 days after the First Commercial Marketing o f any ANDA Drug Product O f The
Same Kind as the First Filer’s ANDA Drug Product if:
(1) such First Filer of an ANDA also agrees to (a) abandon, waive, selectively waive or relinquish
its 180-day Exclusivity Period under such ANDA or (b) grant to another party to the
Agreement the right to exclusively distribute such ANDA Drug Product for a period o f time
not to exceed the 180-day Exclusivity Period under such ANDA, and
(2) Alpharma notifies the Plaintiff States o f such Agreement in accordance with Paragraph V of
this Final Order.
PROVIDED FURTHER THAT nothing in Paragraph IV shall prohibit the resolution o f a Patent
Infringement Claim in which any party to an Agreement resolving such Patent Infringement Claim
' .
.
■
■
1*
agrees to refrain from, or tó limit, for any period of time prior to the expiration o f the patent that is
the basis for the Patent Infringement Claim, such party’s research, development, manufacturing,
marketing, distribution, dr sale of an ANDA th u g Product that is the subject o f such la ten t
Infringement Claim if:
(1) the amount received by such party (“Receiving Party”) has a value o f no more than two million
dollars. ($2,000,000),

;

(2) the total amount given to Receiving Parties by each party tó the Agreement resolving such
Patent Infringement Claim (“Paying Party”) has a value o f no more than the Paying Party’s
expected future litigation Costs to resolve such Patent Infringement Claim, and
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(3) Alph&rma notifies the Plaintiff States of such settlement in accordance with Paragraph V o f this
Final Order.
PROVIDED FURTHER THAT, nothing in Paragraph IV shall prohibit Alpharma from Entering
into any Agreement, if Such Agreement is subject to the reporting obligations o f Section 7A o f the
Clayton Act, 15 U.S.C. § 18a (“HSR Act”), and Alpharma submits a complete and accurate
Notification Letter (as specified in Paragraph V of this Final Order) and a Notification and Report
■ Form pursuant to the HSR Act for such Agreement. Nothing in this Final Order shall be construed
. ■.to relieve Alpharma o f any obligation to comply with the requirements o f the HSR Act or any
other law o f the United States Or o f any Plaintiff State; and any Agreement that violates any law o f
■' the United States or o f any Plaintiff State will continue to be subject to separate legal ¡action for
' Violation o f any such law, without regard to whether it violates this Final Order.
' PROVIDED FURTHER THAT, nothing in Paragraph IV shall prohibit^ in connection with
resolving Apotex, Inc. v. Food and Drug Administration, No. 04-5211 (D.C. Cir. filed June 9,
2004), any Person from agreeing to refrain from marketing, distributing or selling any AND A
brtig Product that references NDA No. 020235 for a period no longer than 180 days following
Alpharma’s First Commercial M arketing of its ANDA Drug Product that references NDA No.
020235.

<

V. Agreements Subject to Notification
IT IS FURTHER ORDERED, ADJUDGED AND DECREED THAT:

li

LfcitjWa

À.

Àlfmàrfflfei Shall notify théPiam tifî States o f each Agreement Sub) ect to Notification that
Alpharma joins, participates in, implements, adheres to, maintains, organizes, enforces or
facilitates at any time after the entry o f this Final Order.

B.

The notification required by Paragraph V.A shall be made within thirty (30) days after the
entry o f this Final Order or within five (5) business days after the Agreement Subject to
■ Notification is executed or otherwise goes into effect, whichever is later.

C,

The notification required by Paragraph V.A of this Final Order shall be in the form of a letter
(“Notification Letter”) submitted to counsel for the State o f Maryland, one o f the Liaison
Counsel for the Plaintiff States, no mote than five (5) days after executing any Agreement
.covered by Paragraph IV and containing the following information:
(1) the docket number and caption name o f this Final Order;
(2) a statement thatthe purpose o f the Notification Letter is to give the Plaintiff States
1notification o f an Agreement as required by Paragraph V this Final Order; '
(3) identification o f all parties involved in the Agreement;
(4) identification of all AND A Drug Products involved in the Agreement;
(5) identification o f all Persons (to thé extent known) who hâve filed an ANDA /
With the PDA (including the status o f such application^)for any ANDA Drug Product O f .
Thé Saine Kind as the ANDA Drug' Produces) involved in the Agreement;
(fi) a copy o f the Agreement; and
(i) identification o f the court, and a copy o f the docket sheet, for every legal action that
involved any pahy to the Agreement and relates to any ANDA Drug Product O f The Same
' Kind as the ANDA Drug Produces) involved in the Agreement.
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D.

W ithin thirty (30) days of the receipt o f a written request from a Liaison Counsel for the
Plaintiff States, Alpharma shall submit to the requesting Liaison Counsel for the Plaintiff
States all documents which wërè prepared by or for any officers) or directors) o f Alpharma
for the purpose of evaluating or analyzing the Agreement covered by Paragraph V.A o f this
Final Order. Alpharma shall retain such documents for the full term o f this Final Order.
VT. Notice and Reporting Requirem ents
IT IS FTJRTHER ORDERED, ADJUDGED AND DECREED THAT Alpharma shall:

A.

File a verified, written report with the Plaintiff States setting forth in detail the manner and
form in which it has complied and is complying with the Final Order: (1) within ninety (90)
days from the date this Final Order is entered, (2) annually thereafter for five (5]Tyears on the
anniversary o f the ¡date this Filial Order is entered, and (3) at such other times as the Plaintiff
States may request by Written notice.

B.

For a period o f five (5) years from the date this Final Order is entered, maintain and make
available to Plaintiff States for inspection and copying upon reasonable notice, records
sufficient to describe in detail any action taken in connection with the activities covered by
this Final Order.

C.

Notify the Plaintiff States at least thirty (30) days prior to any proposed (1) dissolution of
Alpharirta, (2) acquisition, merger or consolidation o f Alpharma, or (3) any other.'change in
Alpharttia that may affect compliance obligations arising out o f this Final Order, Including
but not limited to, assignment or the creation or dissolution o f subsidiaries.

D.

Address each notice and report required by Paragraph VI this Final Order to:

State of Maryland
Chief, Antitrust Division
200 S t Paul Place
Baltimore, MD 21202 ,
State of Colorado
Chief, Antitrust Division
1525 Sherman St,
.
Denver, CO 80203
State o f Ohio
Chief, Antitrust Section
150 E. Gay Street
Columbus, OH 43215

,■
i

State of Florida.
Director, Antitrust Division
PL-01 The Capitol
Tallahassee, FL 32399
State o f Michigan
Assistant in Charge
Special Litigation Division
525 W. OttaWa
P.O. Box 30755
Lansing, MI 48913
E.

i.

Waive any objection to the Plaintiff States’ sharing o f information obtained pursuant to this
Final Order with the Federal Trade Commission and the Commission’s sharing With the
Plaintiff States information obtained pursuant to the Commission’s Final Order and
■Stipulated Injunction resolving the Commission’s complaint against Alpharma filed on
• August 17,2004.
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VIL Termination of Final Order
IT IS F M T M & bteE R E JD , ADJUDGED AND DECREED THAT the Final Order
shall take effect oh, and eJcpire teti (10) years from the date this Final Order is entered.

VDEI. Retention of Jurisdiction
IT IS FURTHER ORDERED, ADJUDGED AND DECREED THAT the Court retains
. jurisdiction o f this matter for purposes Of construction, modification and enforcement o f this Final
. . .. Order.
IX. Costs

V

XT IS FURTHER ORDERED, ADJUDGED AND DECREED THAT Alphaxma shall pay
To Liaison Counsel fdr the Plaintiff States $248,863.25 in attorneys’ fees and costs o f investigating
.

m atter/

Dated:

i.

2004.
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